What is the current size of the multiple myeloma market?

The multiple myeloma market generated USD 24.12 billion in 2025, with projections pointing to USD 25.52 billion by 2030. Read More

Which therapy class is growing fastest?

Cell therapy is the fastest-growing class, advancing at a 10.37% CAGR through 2030 due to strong efficacy and potential single-dose cures. Read More

Why is Asia-Pacific experiencing the highest growth rate?

Aging demographics, broader insurance coverage, and accelerated regulatory approvals drive a 13.89% CAGR for Asia-Pacific between 2025-2030. Read More

How are payers addressing high treatment costs?

Payers increasingly require value-based contracts and real-world evidence, linking payment to durable response and quality-of-life improvements. Read More

What are the main manufacturing challenges for CAR-T therapies?

Limited viral-vector capacity and complex autologous production processes extend lead times and elevate costs, constraining near-term supply. Read More

Which distribution channel is gaining share most rapidly?

Specialty and online pharmacies are expanding at a 13.23% CAGR as they provide integrated support services needed for complex regimens. Read More

Multiple Myeloma Companies

This report lists the top Multiple Myeloma companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Multiple Myeloma industry.

About This Report
- Market Size & Share
- Market Analysis
- Trends and Insights
- Segment Analysis
- Geography Analysis
- Competitive Landscape
- Major Players
- Recent Developments
Table of Contents
SCOPE OF THE REPORT
Market Definition